Roivant Sciences (ROIV) Expected to Announce Quarterly Earnings on Thursday

Roivant Sciences (NASDAQ:ROIV) is expected to be releasing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Roivant Sciences to post earnings of ($0.2996) per share and revenue of $1.9970 million for the quarter. Investors can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Roivant Sciences Stock Up 3.8%

Shares of Roivant Sciences stock opened at $34.59 on Wednesday. Roivant Sciences has a 12 month low of $10.90 and a 12 month high of $37.00. The business has a fifty day simple moving average of $32.80 and a 200 day simple moving average of $29.24. The stock has a market cap of $24.88 billion, a PE ratio of -57.65 and a beta of 1.12.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ROIV. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. TD Cowen lifted their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Finally, Citigroup boosted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.59.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the sale, the director owned 13,701,546 shares in the company, valued at $473,388,414.30. This trade represents a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,055,913 shares of company stock worth $69,639,633 in the last 90 days. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. Bank of Montreal Can raised its holdings in shares of Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after acquiring an additional 516 shares during the period. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Utah Retirement Systems increased its holdings in Roivant Sciences by 3.0% during the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after purchasing an additional 600 shares in the last quarter. UMB Bank n.a. increased its holdings in Roivant Sciences by 10.3% during the 4th quarter. UMB Bank n.a. now owns 6,620 shares of the company’s stock worth $144,000 after purchasing an additional 620 shares in the last quarter. Finally, M&T Bank Corp raised its stake in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.